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Abstract 
Background: Type 2 diabetes mellitus (DM) patients have worse adverse cardiovascular outcomes after Percutane‑
ous Coronary Intervention (PCI). However, the adverse cardiovascular outcomes between insulin‑treated and non‑
insulin treated DM patients have been a subject of debate. We sought to compare the short‑term (<1 year) and long‑
term (≥1 year) cardiovascular outcomes between insulin‑treated and non‑insulin treated DM patients after PCI.
Methods: Medline and Embase databases were searched for studies by typing ‘diabetes and percutaneous coronary 
intervention/PCI’ or ‘insulin‑treated and non‑insulin treated diabetes mellitus and PCI’. Endpoints included adverse 
cardiovascular outcomes reported in these DM patients during the corresponding follow‑up periods. Odd Ratio (OR) 
with 95 % confidence interval (CI) was used to express the pooled effect on discontinuous variables and the pooled 
analyses were performed with RevMan 5.3.
Results: 21 studies have been included in this meta‑analysis consisting of a total of 21,759 diabetic patients (6250 
insulin‑treated and 15,509 non‑insulin treated DM patients). Short term mortality, myocardial infarction, target lesion 
revascularization, major adverse cardiac effects and, stent thrombosis were significantly higher in insulin‑treated 
diabetic patients (OR 1.69, 95 % CI 1.40–2.04, p < 0.00001), (OR 1.40, 95 % CI 1.16–1.70, p = 0.0005), (OR 1.37, 95 % CI 
1.06–1.76, p = 0.02), (OR 1.46, 95 % CI 1.22–1.76, p < 0.0001) and (OR 1.66, 95 % CI 1.16–2.38, p = 0.005) respectively. 
Long‑term cardiovascular outcomes were also significantly higher in insulin‑treated DM patients.
Conclusion: Insulin treatment in these DM patients was associated with a significantly higher short and long‑term 
adverse cardiovascular outcomes after PCI compared to those DM patients not treated by insulin therapy.
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Background
Insulin therapy in Type 2 Diabetes Mellitus (DM) 
is normally indicated either when oral hypoglyce-
mic medications do not seem to be effective (uncon-
trolled blood glucose levels despite the use of oral 
hypoglycemic agents) or initiated especially when 
these patients suffer from diabetic complications. 
However, the effect of insulin therapy on adverse car-
diovascular outcomes in these DM patients has been 
a subject of debate. Several studies have shown that 
compared to non-insulin treated DM patients, insulin-
treated DM patients are associated with many adverse 
cardiovascular outcomes after Percutaneous Coronary 
Intervention (PCI). For example, the study conducted 
by Tada et  al. in [1] concluded that an excess risk of 
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serious cardiovascular events was observed in the 
insulin-treated DM compared to non-insulin treated 
DM patients after PCI [1]. Another study conducted 
by Akin et al., and including patients from the German 
Drug-Eluting Stent (DES.DE) registry revealed that 
even with Drug-Eluting Stents (DES), the annual risks 
for death, Target Vessel Revascularization (TVR), and, 
thrombotic events remained higher in DM patients 
treated with insulin compared to those without insulin 
treatment [2]. However, other studies showed slightly 
different results. Results from the study conducted 
by Kirtane in 2008 showed that rates of stent throm-
bosis and all-cause mortality were similar among 
DM patients treated with DES and Bare Metal Stents 
(BMS) irrespective of insulin-treated or non-insulin 
treated status. The author also precise that there were 
no differences in the 4-year composite rates of death 
or myocardial infarction (MI), death or Q-wave MI, 
or, cardiac death or MI between paclitaxel eluting 
stents and BMS in these DM patients with insulin or 
non-insulin treatment [3]. Therefore, in order to con-
firm whether or not, insulin-treated DM patients have 
more adverse outcomes than non-insulin treated DM 
patients, we sought to compare the short-term and 
long-term adverse cardiovascular outcomes between 
insulin-treated and non-insulin treated DM patients 
after PCI.
Methods
Data sources and search strategy
PubMed and Embase were searched for Randomized 
Controlled Trials (RCTs) and observational studies by 
typing the words or phrases ‘diabetes and percutane-
ous coronary intervention/PCI’ or ‘insulin-treated and 
non-insulin treated diabetes mellitus and PCI’. To fur-
ther enhance this search, the term ‘angioplasty’ has also 
been used. All references of relevant studies were also 
reviewed for relevant articles. No language restriction 
was applied.
Inclusion and exclusion criteria
Studies were included if:
(a) They were RCTs or observational studies dealing 
with insulin-treated and non-insulin treated DM 
patients after PCI irrespective of the types of stents 
implanted.
(b) Adverse cardiovascular outcomes were reported in 
these DM patients.
(c) They had either a short-term follow up period 
(<1  year) or a long-term follow-up period of 
≥1 year after PCI.
Studies were excluded if:
(a) Adverse clinical outcomes were not among the 
clinical endpoints.
(b) They were meta-analyses, case studies or letter to 
editors.
(c) No control group/non-insulin treated DM patients 
were absent.
(d) They did not include data with discontinuous vari-
ables or data which could be easily converted to 
discontinuous variables.
(e) Duplicates.
Definitions, outcomes and follow up periods
Diabetic patients referred to as Type 2 DM patients, were 
defined as patients with a fasting blood glucose (FBG) 
level of >7.0 mmol/L or with oral glucose tolerance test 
(OGTT) level of >11.1 mmol/L at least on two separate 
occasions. In this study, DM patients were divided into 
insulin-treated and non-insulin treated DM patients.
Insulin-treated/insulin-dependent DM patients were 
those who required insulin therapy while non-insulin 
treated/non-insulin dependent DM patients were those 
patients who required or did not require oral hypoglyce-
mic agents but did not receive insulin therapy.
The adverse cardiovascular outcomes were
(a) Death: defined as all-cause mortality including car-
diac and non-cardiac mortality. If death was not 
clearly defined whether it was cardiac or non-car-
diac or both, we have assumed it to be death of all 
causes and have used the data in our study.
(b) Major adverse cardiac effects (MACEs): were 
defined as death of cardiac or procedure-related 
origin, MI, and/or, revascularization after stents 
implantation. Since in only a few studies, data for 
major adverse cardiac and cerebrovascular events 
(MACCEs) have been given, we have considered 
MACEs and MACCEs to be in the same category.
(c) Target lesion revascularization (TLR) and Target 
vessel revascularization (TVR): TLR was defined 
as clinically indicated percutaneous or surgical 
revascularization of the index lesion and TVR con-
cerned the vessel affected. Revascularization was 
clinically indicated if there was >70  % diameter 
stenosis on angiography or >50 % stenosis together 
with a positive stress test or ischemic symptoms.
(d) Myocardial infarction (MI): was defined as re-
infarction which occurred in these diabetic patients 
after PCI. It could be Q-wave and non-Q wave MI 
together, STEMI and NSTEMI together, fatal and 
non-fatal MI or, any of them depending on which 
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one was listed in the studies we have included 
in this meta-analysis. If data concerning only 
non-fatal MI was available, we have omitted and 
excluded them from our study.
(e) Stent thrombosis: Any type of stent thrombosis 
including definite and probable stent thrombosis as 
well as subacute stent thrombosis have been con-
sidered in this study.
Short term follow-up period was defined as a follow-
up period of <1 year. In-hospital follow up has also been 
included in this short-term follow up period. A follow-up 
period of up to 12  months or follow up during a whole 
1 year period was also considered as short term follow-up.
Long term follow-up period was defined as a follow up 
at 1 year or more (≥1 year).
Data extraction and quality assessment
Two authors (P.K.B and N.L) independently reviewed 
the data and assessed the eligibility and methodologi-
cal quality of each eligible trial. Information regarding 
study and patient characteristics, intervention strategies, 
and the pre-specified clinical outcomes was systemati-
cally extracted. Disagreements were discussed between 
the authors, and if the authors could not reach a con-
sensus, disagreements were resolved by the third author 
(M.H.C). The bias risk of trials was assessed with the 
components recommended by the Cochrane Collabora-
tion, including sequence generation of the allocation, 
allocation concealment, blinding of participants, person-
nel, outcome assessors, incomplete outcome data, selec-
tive outcome reporting, and, other sources of bias [4].
Methodological quality and statistical analysis
Study selection, data collection, analysis, and reporting of 
the results were performed using the recommendations 
of the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) statement [5]. Heterogene-
ity across trials was assessed using the Cochrane Q-statis-
tic (p < 0.05 was considered significant) and I2-statistic. I2 
describes the percentage of total variation across studies; 
that is, due to heterogeneity rather than chance. A value of 
0  % indicates no heterogeneity, and larger values indicate 
increased heterogeneity. If I2 was <50 %, fixed effect model 
was used. However, if I2 was >50 %, a random effect model 
was used. Publication bias was visually estimated by assess-
ing funnel plots. We calculated odd ratios (OR) and 95 % 
confidence intervals (CIs) for categorical variables. The 
pooled analyses were performed with RevMan 5.3 software.
Ethics
Ethical approval was not necessary as this study is a Sys-
tematic Review and Meta-Analysis.
Results
Study selection
2432 articles were identified by title and abstract. 16 
additional articles were identified from reference lists 
of appropriate studies. After elimination of duplicates, 
2340 articles were further screened. 2220 articles were 
excluded since they were not related to the title of our 
study. 140 full-text articles were finally assessed for eli-
gibility of which, 119 were further excluded for several 
reasons: they were meta-analyses, case studies or letters 
to editor, insulin-treated and non-insulin treated diabet-
ics were not separated into 2 different groups for com-
parison, they did not report the correct endpoints for our 
study or discontinuous data were not provided. Finally 
21 studies have been selected and included in this meta-
analysis. The flow diagram for this study selection has 
been shown in Fig. 1.
Baseline characteristics
These 21 studies which have been included in this sys-
tematic review and meta-analysis consisted of a total of 
21,759 DM patients including 6250 insulin-treated and 
15,509 non-insulin treated patients. The baseline features 
of each included study have been shown in Table 1.
Dyslipidemia included abnormal lipid or cholesterol 
level or treated hyperlipidemia depending of which data 
have been given in the studies.
A good quality of this meta-analysis is that the studies 
included were mainly articles published in highly quali-
fied Journals such as the Journal of American College 
of Cardiology, the Journal of Circulation, the Ameri-
can Heart Association and the American Journal of 
Cardiology.
According to the baseline characteristics, no significant 
differences have been found between the two groups.
The number of insulin-treated and non-insulin treated 
DM patients as well as their corresponding follow up 
periods have been given in Table 2.
According to Table 2, 12 studies had a short-term fol-
low up period whereas 10 studies had a long-term follow 
up period after PCI.
Main results of this meta‑analysis
The results of this meta-analysis showed that during this 
short-term follow up period (<1  year), insulin-treated 
DM patients had significantly higher cardiovascular 
outcomes: All-cause mortality (OR 1.69, 95  % CI 1.40–
2.04, p  <  0.00001), MI (OR 1.40, 95  % CI 1.16–1.70, 
p = 0.0005), TLR (OR 1.37, 95 % CI 1.06–1.76, p = 0.02), 
TVR (OR 1.41, 95  % CI 1.13–1.76, p =  0.003), MACEs 
(OR 1.46, 95  % CI 1.22–1.76, p  <  0.0001) and, Stent 
thrombosis (OR 1.66, 95 % CI 1.16–2.38, p = 0.005) com-
pared to non-insulin treated DM patients after PCI. The 
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results for the short-term outcomes have been illustrated 
in Fig. 2.
During the long-term follow up (≥1 year), the cardio-
vascular outcomes in insulin-treated DM patients were 
still significantly higher: All-cause mortality (OR 1.69, 
95  % CI 1.44–1.98, p  <  0.00001), MI (OR 1.49, 95  % CI 
1.21–1.83, p  =  0.0001), TLR (OR 1.36, 95  % CI 1.17–
1.58, p < 0.0001), MACEs (OR 1.53, 95 % CI 1.28–1.82, 
p  <  0.00001) and, Stent thrombosis (OR 1.59, 95  % CI 
1.21–2.10, p  =  0.001) compared to non-insulin treated 
DM patients after PCI. The results for the long term out-
comes have been illustrated in Fig. 3.
For all of the above analyses, sensitivity analyses 
yielded consistent results. Based on a visual inspection of 
the funnel plot, there has been no evidence of publication 
bias for the included studies that assessed all clinical end-
points. The funnel plot has been illustrated in Fig. 4.
Discussion
Aim of this study
Type 2 DM patients have worse adverse cardiovascular 
outcomes after PCI [6, 7]. Insulin therapy is appropriate 
for those patients in whom oral hypoglycemic drugs are 
not very effective, and for those type 2 DM patients who 
Fig. 1 The flow diagram of study selection
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suffer from micro-vascular and macro-vascular compli-
cations which are late manifestations of this disease. This 
meta-analysis compares the adverse cardiovascular out-
comes between insulin-treated and non-insulin treated 
DM patients after PCI.
Results of our study
Results from this meta-analysis show that both, the 
short-term and long-term adverse cardiovascular out-
comes such as mortality, MI, TLR, MACEs and stent 
thrombosis are significantly higher in insulin-treated DM 
compared to non-insulin treated DM patients after PCI.
Possible reasons and explanation
Several reasons have been thought to be responsible for 
this significantly higher rate of adverse cardiovascular 
outcomes in these insulin-treated DM patients after PCI. 
First of all, insulin-treated DM patients have worse clini-
cal outcome regardless of the treatment regimen, which 
could either be due to more aggressive disease in these 
patients or an adverse effect of this insulin therapy [8]. 
Normally, insulin therapy is initiated in a more advanced 
stage of diabetes. Logistically, a higher rate of adverse 
outcomes should be expected in these complicated 
patients after PCI.
In addition, studies have shown that insulin-treated 
DM patients had higher body mass index, hemoglobin 
A1c (glycosylated hemoglobin), and, blood urea nitrogen 
(BUN) levels than non-insulin treated DM patients, and 
were more likely to have a history of stroke, hypertension, 
congestive heart failure, and, acute coronary syndrome 
when compared with non-insulin treated DM patients 
[8]. Hence, these co-morbidities could be another reason 
for these increased adverse outcomes in these insulin-
treated DM patients.
Moreover, iatrogenic hyperinsulinemia controls hyper-
glycemia in insulin-treated DM patients but this can also 
promote pro-inflammatory macrophage responses and 
stimulate hormonal over-activation of signal transduc-
tion pathways, which affect progression of atherogenesis 
and disturb hemodynamic control and cardiovascular 
function by disrupting the balanced synthesis and release 
of endothelial mediators [9–11]. This has been explained 
in more details below. At the same time, insulin might be 
a marker of high-risk patients, not only because of more 
severe insulin resistance but also because of more pro-
longed diabetes mellitus.
Normally, endogenous hyperinsulinemia of type 2 DM 
is associated with increased hepatic synthesis of cho-
lesterol and triglycerides [12]. Studies have shown that 
glucose control in type 1 DM often requires exogenous 
insulin in amounts far greater than that secreted by nor-
mal beta-cells. The relation between hyperinsulinemia 
and hepatic markers of atherogenesis was investigated 
by Wang and colleagues in a murine model of type 1 
DM [13]. Although insulin injection significantly raised 
plasma levels of PCSK-9, the rise did not exceed that of 
nondiabetic mice with lower insulin levels. In contrast, 
insulin injection appeared to trigger the release of the 
pro-inflammatory mediators tumor necrosis factor; and 
interleukin-1; in diabetic mice to levels higher than that 
seen in non-diabetic mice. The findings suggest that 
exogenous insulin promotes pro-inflammatory mac-
rophage responses independent of markers of hepatic 
cholesterol processing [13], consistent with earlier clini-
cal findings of increased inflammatory markers in coro-
nary atherectomy specimens from DM patients [14].
Also, insulin treatment in type 2 DM has been asso-
ciated with increased platelet aggregation, a finding of 
particular concern given current controversies about 
ongoing risk for stent thrombosis after DES implantation 
[15].
Another reason for this higher rate of adverse cardio-
vascular outcomes could be a greater prevalence of a fam-
ily history of coronary artery disease in insulin-treated 
DM patients and a lesser prevalence of hyperlipidemia in 
Table 1 shows the baseline characteristics of  each 
included study
IT insulin-treated diabetics, NIT non-insulin treated diabetics, Ht hypertension, 
Ds dyslipidemia, Cs current smoker
Studies Age (year) Male (%) Ht (%) Ds (%) Cs (%)
IT/NIT IT/NIT IT/NIT IT/NIT IT/NIT
Abizaid [30] 63.0/63.0 49.5/63.6 73.3/67.5 60.0/64.0 48.9/48.6
Akin [2] 66.9/66.6 65.4/75.0 92.4/92.6 80.7/83.5 14.9/19.3
Antoniucci [31] 69.0/68.0 65.0/73.0 40.0/43.0 30.0/30.0 17.0/21.0
Dangas [8] 62.6/63.2 61.3/76.5 87.5/83.2 – 17.9/14.7
Hermillier [32] 62.2/62.2 63.5/63.5 81.1/81.1 71.4/71.4 –
Jain [33] 66.6/64.9 62.2/71.8 82.1/77.5 67.9/67.7 13.9/18.0
Kereiakes [34] 63.3/63.3 63.3/63.3 87.0/87.0 82.5/82.5 18.3/18.3
Kirtane [3] 63.0/63.0 64.7/64.7 82.1/82.1 74.0/74.0 18.4/18.4
Kirtane [16] 64.0/64.0 60.4/60.4 90.6/90.6 87.1/87.1 54.1/54.1
Kuchulakanti  
[35]
65.1/65.1 60.5/60.5 89.0/89.0 88.5/88.5 16.0/16.0
Kumar [15] 62.0/67.0 62.0/67.0 94.0/93.0 89.0/92.0 11.0/8.0
Mehran [36] 63.0/66.0 52.0/61.0 77.0/77.0 71.0/67.0 11.0/12.0
Mulukutla [37] 63.5/64.0 50.7/61.5 84.8/83.1 79.5/77.3 16.9/19.4
Nakamura [38] 66.2/67.2 66.2/75.4 68.1/72.0 58.0/60.4 12.1/19.5
Schofer [39] 60.0/62.0 71.0/77.0 73.0/75.0 65.0/72.0 13.0/20.0
Stein [40] 58.0/60.0 53.1/66.1 56.8/63.0 – –
Stone [41] 63.8/63.8 63.2/63.2 83.1/83.1 79.4/79.4 19.6/19.6
Tada [1] 66.7/67.9 67.0/76.0 76.0/78.0 – 16.0/21.0
Witzenbichler 
[42]
64.5/64.5 73.4/73.4 72.3/72.3 60.3/60.3 56.8/56.8
Kappetein [43] 65.4/65.4 71.0/71.0 70.0/70.0 82.0/82.0 16.0/16.0
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non-insulin treated DM patients shown in the study con-
ducted by Kirtane in 2009 [16].
Other researches
Similar to this meta-analysis, a study conducted by Claes-
sen in 2011 showed that patients with insulin-treated DM 
had higher long-term mortality compared to patients 
with non-insulin treated DM (16.6 vs 11.9 %, p < 0.049) 
after PCI [17]. Moreover, the (SIRIUS) trial with 131 
DM patients receiving Sirolimus-Eluting Stent also sup-
ported our results showing a higher MACEs rate (15.8 vs 
6.5 %, p < 0.001), and TLR rate (13.2 vs 4.3 %, p < 0.001 in 
patients requiring insulin compared to those who did not 
require insulin. In the Taxus-IV trial of a paclitaxel-elut-
ing stent, higher rates of overall MACEs were observed 
in insulin-treated compared to non–insulin-treated DM 
patients [18].
A study by Daemen et  al. [19] published in 2007 
showed that all-cause mortality was higher in insulin-
treated DM patients (16.7 vs 9.6 %, p < 0.013) compared 
to those without insulin therapy. However, this study 
found no differences in TLR between these insulin and 
non-insulin treated DM patients [19].
Several studies have reported results which were differ-
ent from our meta-analysis too. Insulin therapy may not 
always be associated with adverse cardiovascular events. 
Recently, several researches have been published on insu-
lin resistance. The study by Trifunovic et al. showed that 
insulin resistance assessed by the Homeostasis Model 
Assessment (HOMA) index during the acute phase of the 
first anterior STEMI in patients without diabetes treated 
by primary PCI is independently associated with poorer 
myocardial reperfusion, impaired coronary microcircula-
tory function, and potentially with larger final infarct size 
[20]. Another study published by Iguchi T et al. suggested 
that insulin resistance might be associated with coronary 
plaque vulnerability [21]. Moreover, the study by Lopez-
de-Andres et  al. showed that higher comorbidity and 
female gender are associated with a higher in-hospital 
mortality in PCI procedures and in-hospital mortality 
was higher in patients without diabetes than those with 
diabetes indicating that maybe insulin therapy is not the 
real cause of adverse outcomes in these patients [22]. 
Also, the study published by Kuramitsu et  al. in 2013 
concluded that post-challenge hyperglycemia is associ-
ated with future cardiovascular events in patients with 
stable angina undergoing PCI [23].
Furthermore, the study by Ong et  al. reported results 
in 293 diabetic patients from the non-concurrent Rapa-
mycin-Eluting Stent Evaluated At Rotterdam Cardiol-
ogy Hospital (RESEARCH) and Taxus-Stent Evaluated 
At Rotterdam Cardiology Hospital [T-SEARCH] regis-
tries who received either sirolimus- or paclitaxel-eluting 
stents. Insulin-treated patients had a higher crude rate of 
MACEs at 1 year compared with other DM patients (27.4 
vs 14.6 %, p < 0.008), but the difference was not signifi-
cant after multivariable adjustment [24].
Another study performed by Berenguer et  al. showed 
higher restenosis rates for insulin-treated DM patients 
after sirolimus-eluting stenting as well as a non-statis-
tically significant difference for the clinical outcome of 
target vessel failure (death, MI, or TVR, 17.4 vs 7.7  %, 
p  <  0.07) [25]. These investigators, however, also noted 
that insulin treatment was not a significant independ-
ent predictor of clinical outcome. Of note, these registry 
studies also had limited power to detect statistical sig-
nificance with only 72 and 46 insulin-treated patients, 
respectively.
Novelty in this study
This meta-analysis compares the cardiovascular out-
comes between insulin-treated and non-insulin treated 
DM patients after PCI. Several meta-analyses compar-
ing BMS and DES in DM patients [26], comparing the 
effectiveness of different types of DES [27, 28], or com-
paring the clinical outcomes in DM patients undergoing 
Table 2 Number of insulin-treated and non-insulin treated 










Abizaid [30] 97 151 During 1 year
Akin [2] 581 1078 During 1 year
Antoniucci [31] 84 82 6 months
Dangas [8] 325 631 1 month, 5 years
Hermillier [32] 105 213 At 1 year
Jain [33] 644 1919 During 1 year
Kereiakes [34] 314 826 At 1 year
Kirtane [3] 265 562 4 years
Kirtane [16] 137 319 At 1 year
Kuchulakanti 
[35]
265 586 6 months
Kumar [15] 115 182 9 months
Mehran [36] 81 114 In‑hospital
Moussa [18] 82 197 9 months
Mulukutla [37] 817 1749 During 1 year
Nakamura [38] 200 647 At 3 years
Schofer [39] 48 117 6 months
Stein [40] 352 781 In hospital
Stone [41] 494 1375 2 years
Tada [1] 996 3404 3 years
Witzenbichler 
[42]
159 434 At 1 year
Kappetein [43] 89 142 5 years
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PCI and Coronary Artery Bypass Grafting (CABG) 
have been conducted but no one has yet conducted a 
meta-analysis between insulin-treated and non-insulin 
treated DMpatients after PCI [29]. Moreover, this meta-
analysis which includes 21,759 DM patients from 9 
RCTs and 12 observational studies, compares both the 
Fig. 2 Forest plot comparing the short term cardiovascular outcomes between insulin‑treated and non‑insulin treated diabetic patients after PCI
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Fig. 3 Forest plot comparing the long term cardiovascular outcomes between insulin‑treated and non‑insulin treated diabetic patients after PCI
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short term and long term cardiovascular outcomes in 
these patients.
Limitations
First of all, due to the limited study number and popu-
lation size of insulin-treated DM patients, the power of 
the analysis might be restricted to some extent. Another 
limitation could be the short term follow up period. In-
hospital outcomes have been included in the short-term 
follow up category along with follow up during a 1 year 
period. This could affect the results of this study to an 
extent. Inclusion of observational studies together with 
RCTs in this meta-analysis is supposed to reduce the risk 
for bias. However, this inclusion of observational studies 
could on the other hand be a limitation in this study.
Conclusion
Insulin treatment in these DM patients was associated 
with a significantly higher short and long-term adverse 
cardiovascular outcomes after PCI compared to those 
DM patients not treated by insulin therapy. Therefore, 
compared to non-insulin treated DM patients, the prog-
nosis in insulin-treated DM patients is not so good after 
PCI.
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